New call-to-action
New call-to-action
New call-to-action

The Value of Patient Input and Perspective in Drug Development

In this video and blog, Janet Woodock highlights how the FDA is placing a high priority on patient input in drug development.

Janet Woodock, MD, Director of the Center for Drug Evaluation and Research at the FDA, recently highlighted how the FDA is placing a high priority on patient input and perspective in the drug development process. The agency recognizes that patients, families, and caregivers are true experts in their disease or syndrome. They have valuable knowledge and information that is being incorporated into the drug review and approval process.

Insights into biggest burdens, priorities for improving quality of life, and risk tolerance are important for accurately representing the the patients perspective when evaluating risk versus benefit of a potential therapy. Members of the FPWR research team were able to see Dr. Woodcock speak at the recent NORD Rare Disease and Orphan Drug Breakthrough Summit in Arlington Virginia.

 

 

FPWR is committed to incorporating the patient/family voice into the development of therapies for PWS. There are several recent and ongoing initiatives in this vein. In the summer of 2014, a Patient Voices Survey was conducted to begin quantifying unmet medical needs and preference for drug development. A summary of over 700 responses from the PWS community weighing in on our greatest challenges can be found here. More recently, a "Caregiver Burden" survey aims to capture information about the financial and emotional burden on families caring for a loved one with PWS and a summary of results is in progress. Both of these were conducted in collaboration with PWSA-USA.

The FPWR family conference this fall included a workshop on the use of "Real World Data". This was part of a PCORI award supporting an in-person workshop as well as a webinar on, “Real World Data Research Readiness: Engaging the Prader-Willi Syndrome Community.” The workshop and webinar brings together patient and stakeholder partners in a co-learning environment.  Families that participated contributed tremendous insidhe and suggestions to inform the development of real world data research in PWS. Keep an eye out for the webinar version which will be taking place in the Spring!

How else can you make your voice heard? Be sure to participate in the Global PWS Registry! Every story is a key piece to our learning about PWS. The Registry is comprehensive database of individuals with PWS aimed at better understanding the full spectrum of PWS characteristics, expediting the completion of clinical trials, determining areas of needed research and treatments to improve the lives of those affected by PWS.

Understanding PWS - Slide Deck

Topics: Research

Jessica Bohonowych

author-image

Jessica Bohonowych is a graduate of Duke University, and holds a PhD in Pharmacology and Toxicology at the University of California, Davis. Incorporating her research background, knowledge of pharmacology and drug development, and teaching experience, Jessica works with Theresa Strong in managing FPWR’s grant portfolio, communicating research results and breakthroughs to our community, aiding in special projects such as the Clinical Trials Initiative and Molecular Resource Center, and is heading the development of the Global PWS Registry.